The Party Committee of the Group organized the study and implementation of the spirit of the Fifth Plenary Session of the 19th CPC Central Committee
Release time:
2020-11-12
The Party Committee of the Group organized to study and implement the spirit of the Fifth Plenary Session of the 19th CPC Central Committee
News from this newspaper 11# June 10 On the afternoon of the 8th, the Party Committee of the Group held an enlarged meeting to learn the spirit of the Fifth Plenary Session of the 19th CPC Central Committee and make arrangements for the next step of study, publicity and implementation. At the meeting of
, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, together with all members of the party committee, members of the management team of the group company, heads of functional departments and some party members, studied the communique of the Fifth Plenary session of the 19th CPC Central Committee and interpreted the spiritual points of the plenary session. Jiang Xiaomeng pointed out that the Fifth Plenary Session of the 19th Central Committee of the Communist Party of China, held in Beijing from October 26 to 29 , was a very important meeting held at an important historical moment when the victory of building a well-off society in an all-round way is in sight and the new journey of building a socialist modern country in an all-round way is about to begin. The "Proposal" of the 14th Five-year Plan, it fully embodies the foresight of the Party Central Committee with Comrade Xi Jinping as the core in planning the future and the historical responsibility of carrying forward the past, and profoundly points out the guidelines, objectives, tasks, and strategic measures for China's development in the coming period. It is of great and far-reaching significance to mobilize and encourage the whole Party and the people of the whole country to continue to seize the important strategic opportunity period and promote the comprehensive construction of a socialist modern country.
In response to the goals and some hot issues raised in the Plenary Communiqué, such as how to achieve the long-term goals of 2035, the key goals of economic and social development during the "14th Five-Year Plan" period, why the emphasis is on adhering to the party's overall leadership, Strengthening the centralized and unified leadership of the Party Central Committee, the main risks and challenges facing economic development in the next five years, how to achieve scientific and technological self-reliance and promote innovation, how to understand the new development pattern of building a double cycle, Jiang Xiaomeng cited the answers of the leaders of relevant central ministries and commissions at the press conference of the plenary session.
Jiang Xiaomeng stressed that China's current development environment is facing profound and complex changes, with new development and changes in opportunities and challenges. The guiding ideology and principles of economic and social development during the 14th Five-Year Plan period put forward by the plenary session and the main objectives of economic and social development during the 14th Five-Year Plan period will have a direct impact on the future development of our enterprises. Party organizations at all levels and all employees at the peak must study and study carefully, find the entry point and direction of work, make every effort to complete the annual work goals, and make preparations for the next year.The person in charge of the party organization of the company's overseas enterprise participated in the study through the video conference system. (this newspaper reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page